Zacks Research Has Negative Outlook of Chemours Q1 Earnings

The Chemours Company (NYSE:CC) – Equities researchers at Zacks Research reduced their Q1 2025 EPS estimates for Chemours in a research report issued on Monday, March 3rd. Zacks Research analyst R. Department now expects that the specialty chemicals company will post earnings of $0.18 per share for the quarter, down from their prior forecast of $0.51. The consensus estimate for Chemours’ current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours’ Q4 2025 earnings at $0.31 EPS, FY2025 earnings at $1.61 EPS, Q1 2026 earnings at $0.45 EPS, Q3 2026 earnings at $0.78 EPS and Q4 2026 earnings at $0.47 EPS.

Several other brokerages also recently commented on CC. Morgan Stanley lowered their target price on shares of Chemours from $25.00 to $22.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $25.00 price target on shares of Chemours in a report on Thursday, December 12th. Truist Financial initiated coverage on shares of Chemours in a report on Tuesday, January 28th. They issued a “buy” rating and a $27.00 price target for the company. Barclays reduced their price target on shares of Chemours from $23.00 to $19.00 and set an “equal weight” rating for the company in a report on Monday, February 24th. Finally, The Goldman Sachs Group reduced their price target on shares of Chemours from $24.00 to $21.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $23.11.

Chemours Stock Up 5.3 %

Shares of NYSE:CC opened at $14.12 on Thursday. Chemours has a 52 week low of $13.31 and a 52 week high of $29.21. The company has a debt-to-equity ratio of 6.70, a quick ratio of 0.92 and a current ratio of 1.68. The company has a market capitalization of $2.11 billion, a PE ratio of 24.76 and a beta of 1.81. The company has a 50 day moving average price of $17.70 and a two-hundred day moving average price of $18.76.

Chemours (NYSE:CC) last posted its quarterly earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $0.01. The business had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.37 billion. Chemours had a net margin of 1.51% and a return on equity of 26.54%.

Hedge Funds Weigh In On Chemours

Large investors have recently modified their holdings of the stock. Corient Private Wealth LLC increased its position in Chemours by 4.7% during the fourth quarter. Corient Private Wealth LLC now owns 13,428 shares of the specialty chemicals company’s stock worth $227,000 after acquiring an additional 604 shares during the period. KBC Group NV increased its position in Chemours by 19.5% during the third quarter. KBC Group NV now owns 4,468 shares of the specialty chemicals company’s stock worth $91,000 after acquiring an additional 728 shares during the period. GAMMA Investing LLC increased its position in Chemours by 99.7% during the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company’s stock worth $26,000 after acquiring an additional 765 shares during the period. HUB Investment Partners LLC increased its holdings in Chemours by 1.4% in the 4th quarter. HUB Investment Partners LLC now owns 58,250 shares of the specialty chemicals company’s stock valued at $984,000 after buying an additional 821 shares during the period. Finally, Itau Unibanco Holding S.A. increased its holdings in Chemours by 39.3% in the 4th quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company’s stock valued at $60,000 after buying an additional 1,003 shares during the period. 76.26% of the stock is owned by institutional investors.

Chemours Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 14th. Stockholders of record on Friday, February 28th will be given a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 7.08%. The ex-dividend date of this dividend is Friday, February 28th. Chemours’s payout ratio is presently 175.44%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.